JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Expression of TCEAL2 is a Novel Prognostic Biomarker and Potential Therapeutic Target in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma

  • 0Pelvic Radiotherapy Department, Meizhou People's Hospital, Meizhou, 514031, Guangdong, China.
Current Medicinal Chemistry +

|

August 28, 2025

|

August 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

TCEAL2 is a potential biomarker for cervical cancer (CESC). High TCEAL2 levels correlate with poor outcomes and impact treatment sensitivity, suggesting its role in cancer progression.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genomics

Background

  • Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) are significant gynecological malignancies with poor survival rates.
  • Current treatments for CESC have limited efficacy, necessitating the identification of novel biomarkers and therapeutic targets.
  • Improving patient prognosis and enabling personalized treatment strategies are critical goals in managing CESC.

Purpose Of The Study

  • To investigate the role of TCEAL2 expression in cervical cancer (CESC).
  • To evaluate TCEAL2 as a potential prognostic biomarker and therapeutic target in CESC.
  • To explore the correlation of TCEAL2 with clinical features, prognosis, and tumor microenvironment in CESC.

Main Methods

  • Analysis of TCEAL2 expression data from The Cancer Genome Atlas (TCGA) across multiple cancer types, with a focus on CESC.
  • Exploration of correlations between TCEAL2 expression and clinical parameters, prognosis, immune infiltration, microsatellite instability (MSI), and mRNA stability (mRNAsi).
  • Validation of TCEAL2 expression in independent datasets (GSE9750) and CESC cell lines using quantitative real-time PCR (qRT-PCR).

Main Results

  • TCEAL2 expression is significantly altered in CESC and associated with advanced pathological M stage and initial treatment failure.
  • Elevated TCEAL2 levels correlate with reduced overall survival (OS) and serve as an independent predictor of unfavorable OS.
  • TCEAL2 expression is linked to key signaling pathways (calcium, oxidative phosphorylation, Wnt) and correlates with immune cell infiltration, MSI, mRNAsi, and inversely with sensitivity to specific drugs.

Conclusions

  • TCEAL2 plays a significant role in CESC progression and influences the tumor microenvironment.
  • TCEAL2's association with immune infiltration and drug sensitivity positions it as a potential prognostic biomarker and therapeutic target for CESC.
  • Further research is warranted to elucidate TCEAL2's molecular mechanisms and validate its clinical utility in CESC management.

Keywords:

Related Concept Videos

Targeted Cancer Therapies 02:57

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy 01:27

659

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment 02:17

6.8K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...